Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

Some therapeutic sectors saw their compound annual growth rate drop 10% or more, deviating from long-term trends. Sales should return to normal growth trajectories as backlogs in procedures continue to clear out.

Partner, Health and Life Sciences, Oliver Wyman

Merck executives share their strategy for embedding health equity across the pharma value chain.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Oliver Wyman
Associate Vice President for Health Equity and Lead, Merck for Mothers
Former Executive Director of Health Equity, Merck

And How Stakeholders Can, Literally, Save the World

Climate change will be the biggest impact on global health. The healthcare industry may not respond in time.

Director, Marsh & McLennan Advantage Insights
Partner, Health and Life Sciences, Oliver Wyman

New Predictions on COVID-19 Vaccines and Herd Immunity

How COVID-19 case counts and vaccines may get us back to normalcy by June.

Partner and Vice Chairman, Financial Services, Americas, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner and CMO, Health and Life Sciences, Oliver Wyman
Managing Partner, Americas, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Software-only products providing free-standing treatment represent a key healthcare opportunity for incumbents.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

Social distancing may be necessary for two years or more. Here's where remote care comes into play.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman